Vital Therapies Inc (NASDAQ:VTL)’s share price traded down 0% during mid-day trading on Monday . The stock traded as low as $0.30 and last traded at $0.30. 169,119 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 9,195,165 shares. The stock had previously closed at $0.30.

VTL has been the topic of several research analyst reports. William Blair raised Vital Therapies from a “market perform” rating to an “outperform” rating in a research report on Monday, August 6th. Cantor Fitzgerald lowered Vital Therapies from an “overweight” rating to a “neutral” rating in a research report on Wednesday, September 12th. BTIG Research reissued a “hold” rating on shares of Vital Therapies in a research report on Thursday, August 9th. BidaskClub lowered Vital Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, September 6th. Finally, ValuEngine raised Vital Therapies from a “hold” rating to a “buy” rating in a research report on Friday, June 29th. Seven equities research analysts have rated the stock with a hold rating, The company has a consensus rating of “Hold” and a consensus price target of $12.00.

The stock has a market capitalization of $12.97 million, a P/E ratio of -0.23 and a beta of 4.16.

Vital Therapies (NASDAQ:VTL) last released its quarterly earnings results on Tuesday, August 7th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. research analysts expect that Vital Therapies Inc will post -1.12 EPS for the current year.

In other Vital Therapies news, Director Muneer A. Satter sold 11,382,277 shares of Vital Therapies stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $0.36, for a total transaction of $4,097,619.72. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Muneer A. Satter sold 447,500 shares of Vital Therapies stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $0.36, for a total value of $161,100.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,902,652 shares of company stock worth $4,284,926. 33.90% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp increased its holdings in shares of Vital Therapies by 12.0% in the first quarter. Northern Trust Corp now owns 83,688 shares of the company’s stock valued at $569,000 after purchasing an additional 8,993 shares during the period. TD Asset Management Inc. increased its holdings in shares of Vital Therapies by 50.2% in the second quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock valued at $249,000 after purchasing an additional 12,144 shares during the period. Citigroup Inc. increased its holdings in shares of Vital Therapies by 1,093.5% in the first quarter. Citigroup Inc. now owns 15,909 shares of the company’s stock valued at $108,000 after purchasing an additional 14,576 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in shares of Vital Therapies in the second quarter valued at approximately $139,000. Finally, Rhumbline Advisers acquired a new position in shares of Vital Therapies in the second quarter valued at approximately $183,000. 32.62% of the stock is currently owned by institutional investors.

Vital Therapies Company Profile (NASDAQ:VTL)

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Further Reading: Market Capitalization

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.